

Type of the Paper (Article)

The Effect of Amniotic Fluid On Hair Follicle Growth

Gamze Tumentemur¹, Elif Ganime Aygun², Bulut Yurtsever³, Didem Cakirsoy³ and Ercument Ovali³

¹Acibadem Mehmet Ali Aydinlar University, Vocational School of Health Services, Istanbul, Turkey ; gtumentemur.acibadem@gmail.com

²Acibadem Mehmet Ali Aydinlar University Atakent Hospital, Department of Obstetrics and Gynecology, Istanbul, Turkey; elif.aygun@acibadem.com

³Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey
bulut.yurtsever@acibademlabcell.com
didemcakirsoy@gmail.com
ercumentovali@acibadem.com

Correspondence to author

Gamze Tümentemur
Acibadem Mehmet Ali Aydinlar University, Vocational School of Health Services, Istanbul, Turkey
E-mail: gamze.tumentemur@acibadem.edu.tr

Abstract: Human amniotic fluid stem cell (hAFSC) exhibit significantly as a new treatment modality in hair loss, wound, scar and regenerative plastic surgery/dermatology. The difference of our study from previous amniotic fluid studies on the hair growth model was studied through the direct effect of human amniotic fluid (hAF). In our study, amniotic fluid was made acellular, pooled and frozen, making it more standardized in terms of its contents. Therefore, the present study is aimed at investigating the efficacy and safety of amniotic fluid in hair loss model on rat. Using the hair loss model rats, we investigated the therapeutic potential of freezing amniotic fluid (FAF) and freezing gamma irradiated amniotic fluid (FAFI). Our results showed that FAF and especially FAFI increased number of total hair follicles and accelerated number of transition to anagenic hair follicle. We observed that increased rate of arginase+1(Arg+1)/CD68 activity around the hair follicles treated with hAF. Our study suggests that FAFI may represent a safe and effective tool for increasing hair follicle and accelerating to anagen stage during hair loss model.

Keywords: amniotic fluid, gamma irradiation, hair follicle

1. Introduction

Hair loss (alopecia) is a common birth, hormonal, traumatic and iatrogenic problem. Alopecia Areata (AA) is an autoimmune hair disorder [1] and androgenic alopecia (AGA) is a condition that occurs with the effect of androgens, can be seen progresses with hair loss in male genders. Oral and topical drug or surgical options for the treatment of alopecia areata. Topical drug treatment includes corticosteroids, minoxidil and immunotherapy [2]. Contact immunotherapy with diphenylcyclopropenone is mainly used for limited hair loss [3]. However, these drugs have inadequate treatment methods because of side effects and limited therapeutic uses [4]. Recently, the efficacy of many cytokine-targeted drugs has been described in patients with AA [5]. Further, autologous single follicle and follicular unit transplantation has been a reliable surgical option, but the number of donor follicles limits this method.

Hair follicle (HF) is a mini-organ containing epidermal and dermal layers that go through hair cycle processes to produce new hair continuously throughout the life of the organism [6]. Hair follicle stem cell (HFSC) niche is responsible for maintaining tissue homeostasis in response to physiological and pathological conditions. It contains many cell types, including intradermal adipocytes [7], dermal fibroblasts [6], cutaneous blood vessels [8], macrophages and endothelial cells [9]. Immune cells in the hair follicle epithelium are called the hair follicle immune system [10]. Macrophages and T lymphocytes are a cutaneous immune cells. Dermal papilla (DP) provides signals that control hair follicle development and contribute to determining the size, shape and pigmentation of the hair shaft [11;12] as well as acting as a reservoir of stem cells [13]. An altered the DP microenvironment can lead to human skin hair loss, such as androgenic or chemically induced hair loss [14; 15;16]. The hair cycle is divided into three phases: growth and regeneration, regression, resting phase (anagen, catagen and telogen, respectively). There is a connection between macrophages and the regulation of the HF cycle, particularly between anagen-catagen transition [10;17]. During the catagen phase, macrophages digest the excess extracellular matrix and stimulate follicular stem cells, thus stimulating HF to enter the anagen phase [18]. Macrophages entering the anagen stage perform collagen phagocytosis to remodelling the matrix [19].

Hair cycle and regeneration which are the tissue restructuring process that includes growth factors, cytokines, hormones, adhesion molecules and related enzymes [20]. Growth factors (Insulin like growth factor-(IGF-1), Platelet derived growth factor (PDGF) and fibroblast growth factor (FGF) play important roles in HF morphogenesis by acting on stem cells in the bulge area of hair follicles [21; 22]. Although positive effects of growth factors on hair follicle regeneration have been reported, their high cost limits using in clinical applications [23]. The use of stem cells and growth factors in cell-based therapies are accepted as a therapeutic strategy in damaged tissue repair due to their direct cellular

effects [24]. But human amnion-derived stem cells (hADSCs), human amniotic epithelial stem cells (hAESC) and human amniotic mesenchymal stem cells (hAMSCs), have great advantages compared to other stem cells such as regeneration, tumorigenicity former. Moreover, there is no ethical provision or legal restrictions as embryonic stem cells are obtained from an adult source [25;26]. Furthermore their high proliferation capacity, multipotency, immunomodulatory effects make them a promising source of stem cells for cell therapy in various diseases [27; 28; 29; 30; 31]. As medical wastes, AFSCs can be obtained via amniocentesis during the pregnancy intermediate stage or cesarean section [32]. Ability of AFSCs to multi-differentiate is limited, but they do not have the risk of teratoma formation [33].

Amniotic fluid (AF) is a mixed biological fluid containing protein, lipid, carbohydrates, enzymes, urea, electrolytes, hormones, growth factors (IGF-1, PDGF, IL-8, IL-6, transforming growth factor (TGF)- β , TNF- α , vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF)), stem cell and stem cell exosomes [34; 35; 36; 37; 38; 39; 40; 41; 42]. AF and Amniotic fluid-derived mesenchymal stem cells (AF-MSCS) which are known to be important in normal wound healing, are thought to trigger cell proliferation, differentiation, angiogenesis and chemotaxis, which are necessary for new hair follicle growth [41]. AFSC and its cytokines especially macrophages involved in HF mesenchyme, have interesting regulatory properties in hair follicle homeostasis [17; 43; 44]. Disrupting between this connection may lead to clinically important forms of immune-mediated alopecia [45; 46; 47].

Studies of amniotic fluid on alopecia have been demonstrated through the stem cell effect of this fluid. Our study, amniotic fluid was made acellular and pooled, making it more standardized in terms of its contents. In terms of content, it has been made safe even against viral and pyrogenic contamination [48] due to gamma radiation. Therefore, it was designed to investigate the effect on the rat hair follicle development model by creating a longer shelf life and more effective form.

2. Results

2.1. Amniotic fluid analysis results

As shown Fig. 2A, TGF-B ($p < 0.00714$) and VEGF ($p < 0.00003$) levels in FAFI group were higher than FAF group. When Th1 type cytokines were divided by the amounts of Th2 type cytokines, the values were found to be below one (Fig. 1B).




Figure 1. A statistical comparison of the cytokine levels of VEGF, EGF, PDGF-B, TNF- α , TGF- β , FGF-B, IL 1 and IL 6 levels in FAF and FAFI groups in an experimental hair follicle development model (ng/L) (A). Our data show that transition of M1 to M2 in treated with hAF groups that the amniotic fluid is contain high exosome content ($1.14e10 \pm 0.531e10$) (B).

2.2. Macrophage 2 Profile of Amniotic Fluid and Macrophage 2 Profile in Tissue

Our study showed that Th2 cytokines are linked to changes in expression levels of these cytokines (Fig. 2 A). Our results that the Th2 type cytokines of the concentration of 10% and above amniotic fluid can induce the M1 to M2 phenotype switch in macrophages (Fig. 2B). The figure shows the expression of the M2 macrophage marker Arg⁺ cells around dermal papilla (black arrow) and stroma (red arrowhead) in samples (A:FAFI; B: FAF; C:CNT). The figure shows the expression of the CD68 ⁺ cells around dermal papilla (black arrowhead) in samples (D:FAFI; E: FAF; F:CNT) Scale Bars, 400 μ m (Fig. 2C). A significantly increased rate of Arg⁺/CD68 cells found in the FAF and FAFI specimens compared to cnt group (*p<0,05) All data are reported as the mean \pm SD (Fig. 2D).




Figure 2. Differential hAF expression with macrophage differentiation (A). These data showed that amniotic fluid contains Th2 type cytokines (B). Macrophage cell counts in skin specimens (C). The figure shows the Arg⁺ and CD68⁺ cells count (cells per mm² specimen area) in the whole analysed area in the stroma compartment of the skin specimens (D). The ANOVA test's P-value results are shown.

2.3. Macroscopic and Microscopic Analysis Results

2.3.1. Effects of the FAF and FAFI on transition to anagen phase in rat

Comparison of hair follicle pattern in each group on macroscopic evaluation histological observation to vertical view of hair follicles from the dorsal portion of rats were clearly visible (Fig. 3A-C). Compared to the cnt group, the transition to the anagen phase was accelerated (Fig. 3B-D) in the hAF-administered groups (Fig. 3D). At day 21, the hair follicle in the cnt group were in the early anagen phase as hair bulb in the dermis. The hair follicles in the FAF and FAFI groups, were in the late anagen phase and displayed the largest hair bulb size, the deepest hair follicle in the subcutis, and the newly formed hair shaft reaching the level directly below the sebaceous gland. Transition to anagen phase of hair follicle was quantified using histology images with Image J software (D-10 \times). All data are reported

as the mean \pm SD. *: $p < 0,05$; **: $p < 0,0001$ compared with control, ***: $p < 0,0001$ compared with FAF group.

2.3.2. Effects of the FAF and FAFI on hair growth in rat

We performed a histological evaluation hair follicles and collagen fibers using H&E and Masson staining respectively (Fig. 3E-F). In this model, more hair follicle regeneration was detected in the groups treated with hAF compared to the cnt group (Fig. 3E). Especially FAFI and FAF group exhibited a lower level of collagen fibers accumulation, which was more neatly arranged, compared with that in the cnt group (Fig. 3F). In the representative longitudinal sections, the number of hair follicles were significantly increased in the FAFI and FAF group compared to the cnt group (respectively $p < 0.001$ $p < 0.0008$) (Fig. 3G). In addition, the number of hair follicles in the FAFI group was significantly greater than FAF group (Fig. 3G).

2.3.3. Effects of the FAF and FAFI on adipocyte and dermal layer in rat

We performed a histological evaluation of the thickness of dermal and adipocyte layer using H&E staining (Fig. 3H). We quantified the thickness of the dermal and adipocyte layer in dorsal rat skin on 21th day (Fig. 3I-J). There was no change the dermal layer between all the groups ($p > 0.005$) (Fig. 3I). We showed that the adipocyte layer increased in thickness during HF morphogenesis in the FAFI and FAF groups ($p < 0.005$) (Fig. 3J).




Figure 3. The black boxes show the hair follicle development on rat (A) and anagen stages in the sections (B-C). The rat hair follicle development was evaluated by H&E staining (B), masson trichrome (C) and anagen scoring (D). Typical photos of dorsal skin (left panel), histological analysis (right panel) (A: FAFI B: FAF, C: Cnt×100). Representative photomicrographs stained with H&E (E) and masson trichrome (F) of the transverse sections and hair follicle scoring (G). After 21 days, total hair follicle in the skin was analysed, number total hair follicles was quantified using histology images with image J software (C,10×). (A: FAFI, B: FAF and C: Cnt groups) ×100. $p < 0,001$ **: $p < 0,0008$ compared to cnt group ***: $p < 0,04$ compared to FAF group. Relationship between the thickness of dermal layer and the thickness of the dermal adipocyte layer. Double-headed arrows indicate adipocyte layer, whereas bars indicate dermal layer (H). cnt (A), FAF (B), and FAFI (C) (H&E Scale bar, 200 µm). Quantification of the dermal (I) and the adipocyte layer thickness (J) in rat. Between the all groups, no different of dermal layers thickness layer ($p > 0,05$). Thickness of adipocyte layer that significantly increased FAF and FAFI groups compared to cnt group (* $p < 0,05$) (J). Two-way ANOVA followed by Bonferroni's multiple comparison test. All data are reported as the mean ± SD.

3. Discussion

The present study provides the first report of hair growth and transition to anagen phase promotion by hAF whether FAF and FAFI groups can effective in promoting hair growth, were

investigated. However, it is well known that stem cell of hAF has the activity on not only hair follicle regeneration but also transition of hair follicle from catagen to anagen [41; 51; 52; 53]. The present investigation well documented the direct effect of hAF on the hair growth. A striking finding in our study was that hAF promoted catagen-to-anagen transition. Our current histological analysis suggest that hAF was accelerated hair follicle regeneration and reduce collagen fiber deposition. Furthermore, the significant anagen transition and hair growth were seen in FAFI group. There are two points under discussion in terms of these findings. The first is the question of why irradiated group is more effective than non-irradiated group. This previous study show that gamma irradiation can cause growth factors to be kept more stable by inhibiting the protease activity that causes the destruction of active substances in a liquid [48]. Our present finding was also related to this protective effect of gamma irradiation.

Treatment of hair loss using growth factors show interesting activity in promoting hair growth. Choi et al. reported the TGF β family is very important for HF morphogenesis and hair cycle by triggering HF formation with DP activation [54]. In addition, TGF- β has been reported to increase Arg activity [55] and that was detected in the anagen hair follicles tested [56]. Several studies have indicated that VEGF, FGF2 and HGF were related to angiogenesis stimulating hair follicle proliferation [8; 57; 58; 59;60; 51; 62;63] and pro-angiogenic factor could promote anagen transition [64; 65]. Another previous study showed that Minoxidil, one of the pharmaceutical treatments approved for the treatment of alopecia, could promote hair growth by regulating VEGF expression in hair dermal papilla cells [66] and stimulated the transition to anagen [56]. AFMSC secrete MCP-1, IL-8, IL-6, EGF, SDF-1 and VEGF into the conditioned medium, which plays a vital role in angiogenesis [67]. Our data indicate that TGF- β and VEGF levels increased in the FAFI group, was remarkable, and this increase accelerated the transition to anagen phase and hair follicle growth, as stated in other studies. Furthermore, phagocytosis of cellular debris by M1 macrophages can promote production of TGF- β , one of the Th2 cytokines, while reducing expression TNF- α of the Th1 cytokines, reflecting their transition to the M2 phenotype [68]. In particular, the M1/M2 balance plays a critical role in determining the balance

between fibrosis, inflammation/regeneration damage, together with the cytokine microenvironment. M2 polarization can be obtained in vitro with M-CSF, IL-4, IL-6, IL-10, IL-13, IL-33 and/or TGF- β , Arg+1 [69;70; 71; 72; 73; 74; 75; 76; 77; 78]. According to the concept of M1/M2 polarization IFN- γ , TNF- α and IL-1 β are possible factors for the M1 macrophage activation [79]. A glycoprotein called CD68 is found on lysosomal membranes, specifically on the phagosomes in macrophages; its increased expression suggests improved phagocytosis [80] that is crucial in the process of tissue repair and wound healing. According to these results, our data showed that TGF- β was more prominent in the FAFI group so that induced M2 polarization. In addition, $\geq 10\%$ of amniotic fluid concentrations were found to be related with the M1 to M2 phenotype switch in macrophages. In parallel with our study, Tan et al. [84; 85] reported that conversion of M1 to M2 in amnion epithelial cells content. M1-/M2-macrophages functionally correspond to Th1 and Th2, respectively [83]. In our study showed that the Th2 cytokine profile of the amniotic fluid was associated with M2 phenotype. Despite these limitations, hAF-conditioned media significantly altered the phenotype of macrophages toward an M2. Previous studies reported that AFSCs can provide protection by modulating immune function, especially by modulating macrophage recruitment and phenotype (by converting M1 macrophages to M2 macrophages) [84; 85; 86; 87]. According to researchers by Th2 cytokines increase the ornithine and urea production of arginase, which in turn increases macrophage arginine metabolism [88; 89].

In this study, we examined hAF treatment increased Arg+1 expression was observed around the hair follicles, and hair follicle was showed in the anagen phase especially in FAFI group. Our data indicated the expression of Arg+1, which is necessary in the regenerative hair follicle to demonstrate the activation of the M2 phenotype. Our study showed that CD68 was used marker to detect macrophages although other studies show that CD68 define as an M1 marker [90; 91]. We also observed that the expression of CD68 was observed in cnt group. These data demonstrate that CD68 associated with hair loss model.

HF degeneration is based on an anagen-related increase in macrophage numbers [19;92]. Previous study reported that skin-resident macrophages activated epithelial hair follicle stem cells that contribute to hair regeneration and induce anagen stage [44]. Chu et al. reported that by destroying M2

macrophages in mouse skin, hair regeneration was impaired but also it has been observed that there is an anagen onset when m2 infusion is performed so hair growth was observed in proportion to the number of M2 macrophages transplanted [23]. Our findings parallel with previous reports that the number of perifollicular Arg+1 as a used m2 marker increased during anagen and significantly decreased during catagen and reached the lowest levels during the telogen phase [43;93].

Our data showed that the second factor enabled the transition of M1 to M2 in hAF treated groups was that the amniotic fluid contains high exosome content ($1.14e^{10} \pm 0.531e^{10}$). Indeed, in previous study showed that hAFSC exosomes contain HGF and TGF- β through characterized the extracellular vesicles secreted by AFSC [94]. Furthermore, hAFSC-exosomes treatment improved the regeneration levels of hair follicles, nerves and vessels [53].

Several studies have indicated that pre-adipocyte proliferation can be stimulated through angiogenesis [8], or cytokines such as PDGF, EGF, IGF1 and FGF [7; 95; 96], which activate dermal papilla cells to promote hair growth cycle and transition to anagen phase [6 ;7]. In our findings, thickness of adipocyte layer increased in the hAF-administered groups. Our data and previous findings [6 ; 7; 95; 96; 97; 98; 99; 100; 101; 102; 103] showed that thickness of dermal adipocyte layer increased during anagen phase but decreased during catagen and telogen phase. There is also evidence that immature dermal adipocytes activate HF stem cells to initiate the hair growth cycle [7]. In addition, the down growth of the HF during anagen may be facilitated by the presence of an adipocyte layer separating the reticular dermis from the underlying striated muscle, the panniculus carnosus.

In summary, we observed that the exosome content of the amniotic fluid and the contribution of growth factors enabled the conversion of M1 to M2 in the hair regeneration, stimulating the M2 polarization and increase in dermal adipocyte layer, which in turn stimulates the development of hair follicles. It is also thought that while gamma irradiation of the amniotic fluid increases the effectiveness of the product, possibly through protease inactivation, it also provides a safer product. These findings suggest that pooled and irradiated hAF may be involved in the clinical treatment of alopecia and in the pathobiology of hair follicle growth disorders. These findings are planned to be tested in a clinical trial. A new focus on irradiated amniotic fluid, which is safe, easily accessible and without provoking ethical concerns if applied in the clinic, promises to enrich not only translational hair research but also many

other research fields as a model. In conclusion, our study revealed that hAF supports the hair follicle through cytokine, M2 and the extracellular vesicle. All these properties make them a promising source of FAFI for cell therapy and regenerative medicine.

4. Materials and Methods

4.1. Identification, Collection and Preparation of Amniotic Fluid Forms

hAF samples taken during cesarean section from 10 different donors who had previously approved amniotic fluid collection from the operating room of Acibadem Mehmet Ali Aydınlar University Atakent Hospital were transferred to the laboratory at 4°C. Pooling the amniotic fluid, which has low immunogenicity, from different donors further reduces the immunogenicity. Generally, it is recommended that relevant examination should be carried out before collecting hAF from healthy pregnant women, to avoid AF from patients with metabolic diseases. Researchers must also ensure that the hAF is free from viral such as hepatitis B and pathogenic bacterial infection [49]. Approximately 2 to 5 mL of hAF obtained via amniocentesis in the second trimester of pregnancy. Amniotic fluid was first passed through a 0.45 µl and then 0.22 µl filter in a laminar air flow cabin. An equal amount of pool was created by melting.

4.2. Preparation of Amniotic Fluid Forms (Fig.4)

FAF: Prepared amniotic fluid samples described above were dissolved into 2 ml 5 ml vials and then stored at -80 °C until the study period. (represents non-irradiated pool samples).

FAFI: FAF was exposed to 25 Kgray gamma radiation (irradiated FAF) in dry ice at -80°C.

Before use, the contents of the vial were resuspended with 1cc sterile bidistilled water and used within 2 hours.




Figure 4. Schematic representation of hAF preparation. (1) Collecting amniotic fluid from at least three different sources. (2) Centrifuging amniotic fluids for the removal of macroparticles. (3) Staged filtration of centrifuged amniotic fluid. (4) Pooling of amniotic fluids from different sources together. (5) Freezing of the amniotic fluid at -80°C to -40°C . (6) Irradiation in frozen form between 25-35 Kgy. (7) hAF was applied subcutaneously.

4.3. *In vivo* Animal and Experimental Design- Hair regeneration model

Our study Wistar albino female rats (6-8 weeks, weighing 250-300 g) were obtained with follow up with Acibadem Mehmet Ali Aydinlar University DEHAM (2019-32). The rats were anesthetized with 3% pentobarbital sodium (30 mg/kg) and dorsal skin hairs in rat were mechanical depilation. In experiment, rats were randomly assigned to 3 main groups (n = 7/group). (1) Cnt, The test group included a control group treated with normal saline; (2) Frozen amniotic fluid treated group; (3) Frozen irradiated amniotic fluid treated group (1 cc) subcutaneously to the on days 1, 3 and 5. Rats kept in temperature control and 12- hour light dark cycle and standart feeding in the nest. We considered all probable side effects including redness, swelling and rash during the experiment period. The rats were sacrificed and skin tissues were obtained on day 21. Photos were taken 21th days to record for macroscopic analyses. animals were anesthetized with subcutaneous injection of ketamine (100 mg/kg) and xylazine (5 mg/kg). They were horizontal biopsies were taken from the center of treatment areas.

After anesthesia and sacrificed according to the standart method. For histological analysis, dorsal skin samples were collected for each animal, samples were examined in a blinded fashion.

4.4. Amniotic fluid analysis: In the types of amniotic fluid used;

4.4.1. *Cytokine ELISA Assay in Amniotic fluid*

Protein standards for human growth factor (VEGF, EGF, PDGF-B, TGF-B, FGF-B, IL-1, IL-6) elisa strip (signosis) II (Cat# EA-1102). Add 200ul of Diluent buffer the wells of the first strip, and add 100ul of Diluent buffer to the wells of the rest strips according with the manufacturer's protocol. The results were expressed as ng/l.

4.4.2. *Cytokine Bead Array (CBA) from Amniotic Fluid:Th1/Th2 cytokine ratios*

Tumor necrosis factor alfa (TNF- α)/IL-10, TNF- α /IL-6, IFN- γ /IL-6, interferon-alfa (IFN- α)/IL6, granulocyte macrophage stimulating factor (GMCSF)/IL-6, GMCSF/IL-10, GMCSF/IL-9 cytokine ratios of 1:2 diluted amniotic fluid were evaluated by the cytokine bead array (Miltenyi Biotec MACSPlex Cytokine 12 Kit, human; cat #130-099-169) in accordance with the manufacturer's protocol. The experiment is repeated 3 times. Flow analysis were performed at Beckman coulter.

4.4.3. *Amniotic fluid induced macrophage differentiation*

Peripheral blood mononuclear cell (PBMC) was isolated from whole blood collected in citrate tube by ficoll gradient method (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). 500.000 PBMC /well was inoculated in 24 well plate in 1 ml. After 2 hours of incubation, suspended cells were dischared and adherent monocytes were observed. Dilutions were prepared with DMEM medium so that amniotic fluids were at a final concentration of 0%, 5%, 10%, and 20%. After 24 hours of incubation, the adheren

monocytes were collected with trypsin and prepared for flow cytometry analysis. CD14-APC (cat#982506), CD86-Perpcy7 (cat#374209), CD206-FITC (cat#141703). Flow analysis were performed at Beckman coulter. Student t-test analysis were performed.

4.4.4. Nanoparticle Tracking Analysis (NTA)

Microvesicle number was determined in amniotic fluid by using Te NANOSIGHT NS300 (Amesbury, UK). Samples were diluted with distilled water at a 1:10 ratio and transferred to NANOSIGHT cuvette as 1 ml. Measurements were performed at room temperature with 5 different 60-s video recording and were repeated 3 times.

4.5. Histopathological sampling analyzes

4.5.1. Histochemical and Immunohistochemical stainings

Skin samples were fixed in 10% buffered neutral formol for 48 hours. The detected tissue samples were dehydrated by passing through alcohol series according to the histological tissue follow-up method, and after clearing in xylol, they were embedded in paraffin. Serial sections of 5 micron thickness were taken [50].

4.5.2. Hematoxylin-Eosin (H&E) staining

Hair follicle parameters were stained with H&E (H3136 Sigma-Aldrich Hematoxylin and E4009 Sigma-Aldrich Eosin Y). Dermis-dermal adipocyte layer thickness and the numbers of hair follicles and anagen stages were counted in three areas (9 sections) from a biopsy on 3 random fields in 1 section using a high power microscope field by a histologist who was blinded to the codes.

4.5.3. Masson-Trichrome staining

Collagen fibers were stained with Masson's Trichrome staining (HT15-1KT, Sigma) kit to observe. Stained sections were evaluated for collagen determination in light microscopic images.

4.5.4. Immunohistochemical staining

Sections of 5 μm thickness obtained from the selected paraffin blocks were taken to poly-L-Lysine coated slides and kept in an oven at 37 $^{\circ}\text{C}$ for 1 night. Afterwards, deparaffinized sections were placed in xylene for 10 minutes and dehydrated by keeping them in 96% pure alcohol for 5 minutes. It was then washed in distilled water for 2 minutes. Following this procedure, in order to ensure antigen retrieval, it was heated in citrated buffer (ph: 6) solution at 98 $^{\circ}\text{C}$ for 20 minutes and cooled at room temperature for 20 minutes in the same buffer. Afterwards, IHC staining was started. First, to eliminate endogenous peroxidase activity, it was blocked with 3% hydrogen peroxide, incubated for 20 minutes

and washed with Phosphate Buffer Solution (PBS) for 5 minutes. Afterwards, protein block (Large Volume Ultra V Block, TA-125-UB®, Lab Vision Corporation, Fremont, CA, USA) was applied for 5 minutes. Following this procedure, before the sections were washed, the blocking solution was shaken off and the primary antibodies Arginase (Arg1 biocare cat#ACI3058) and CD68 (Dako cat#M0814) were applied. Afterwards, primary antibodies were washed in PBS for 5 minutes, secondary antibodies were dripped and incubated for 20 minutes. After washing for 5 minutes in PBS again, tertiary antibody was dropped and left incubated for 20 minutes. The 5 min PBS wash was repeated. Afterwards, chromogen was added to diaminobenzidine (DAB), incubated for 5-15 minutes and washed in distilled water. Tissues were counterstained in Mayer's Hematoxylin for 1 min. Then it was washed in distilled water for 2-5 minutes and passed through alcohol. The air-dried preparations were placed in xylene, covered with entellan, and used for the specified measurements.

4.5.5. Quantitative histomorphometry

Individual hair follicles in photomicrographs of H&E stained longitudinal sections of every rat. In photomicrographs in the same region (1300 μm width) of the hair follicles were counted. In each group, the percentage of hair follicles that were in a particular anagen stage was calculated.

4.5.6. Cell counting of Arg+1/CD68-polarized macrophages in in vivo skin analogs

In the sections, CD68 antibody staining evaluated as macrophage and Arg1 antibody staining evaluated as M2 rat macrophages of the cell density. In 9 different sections of each skin analog, 3 randomly selected were counted at 10× high-power fields. Cells showing distinct immunopositive reactions for CD68 and Arg+1 were counted per 0.2 mm² from randomly selected areas in the FAF, FAFI and Cnt groups. The average total number of CD68 or Arg+1 positive cells quantified per high-power field of a skin section was used to express immune cell density. Results are given as the mean and standard deviation (SD).

Istatistical Analysis

The outcomes are shown as mean standard deviation (SD). One-way analysis of variance (ANOVA) was used to analyze the data. For all of our statistical analyses, we used SPSS version 23 the p-value.

5. Conclusions

As an alternative to cell therapy, especially gamma irradiated pooled hAF may be beneficial in hair follicle regeneration treatments in the clinic. Moreover, hAF significantly enhanced their applications in experimental research and clinical practice.

Abbreviations

Amniotic fluid: AF
Alopecia Areata: AA
Androgenic alopecia: AGA
Control: Cnt
Dermal papilla: DP
Epidermal growth factor: EGF
Fibroblast growth factor: FGF-2
Granulocyte macrophage stimulating factor: GMCSF Hair follicle stem cell: HFSC
Hair follicle: HF
Hematoxylin-Eosin: H&E
Human amnion-derived stem cells: hADSCs
Human amniotic epithelial stem cells: hAESC
Human amniotic mesenchymal stem cells: hAMSCs
Human amniotic fluid stem cell: hAFSC
Human amniotic fluid : hAF
Interleukin: IL
Irradiated Frozen Amniotic fluid: FAFI
Interferon-gamma: IFN- γ
Interferon-alfa: IFN- α
Insulin-like growth factor-1: IGF-1
Frozen Amniotic Fluid: FAF
Macrophage2: M2
Macrophage 1: M1
Nanoparticle Tracking Analysis: NTA
Transforming growth factor: TGF- β ,
Tumor necrosis factor: TNF- α ,
Platelet-derived growth factor: PDGF
Peripheral blood mononuclear cell: PBMC
Vascular endothelial growth factor: VEG

6. Patents

National (2022/009965) and international (PCT/TR2022/050661) patent numbers of this method have been received.

Author Contributions:

“Conceptualization, GTT. and EO.; methodology, GTT;EO.; software, GTT;EO.; validation, GTT;EO.; formal analysis, GTT. and EO.; investigation, GTT; BY;EG;DC.; resources, GTT; data curation, GTT.; writing—original draft preparation, GTT. EO.; writing—review and editing, GTT. and EO.; visualization, GTT. and EO.; supervision, GTT. and EO.; project administration GTT. and EO.; funding acquisition, EO.

Funding: “This research received no external funding”

Institutional Review Board Statement: The ethical approval of this study was authorized by the Acibadem Mehmet Ali Aydinlar University Local Ethics Committee for Animal Experiments (ACU-HADYEK) with the decision number 2019/32 on the 12th of March 2019. All procedures in this study were performed in accordance with the 1964 Helsinki Declaration and its later amendments.

Acknowledgments: In this section, you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments).

Conflicts of Interest: Declare conflicts of interest or state “The authors declare no conflict of interest.”

REFERENCES

1. Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM et al. (). Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. *J Am Acad Dermatol* 2018;78:1-12
2. Meah N., Wall D., York K., Bhojru B., Bokhari L., Sigall D.A., Bergfeld W.F., Betz R.C., Blume-Peytavi U., Callender V., et al. The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. *J. Am. Acad. Dermatol.* 2020;83:123–130. doi: 10.1016/j.jaad.2020.03.004.
3. Cranwell W.C., Lai V.W., Photiou L., Meah N., Wall D., Rathnayake D., Joseph S., Chitreddy V., Gunatheesan S., Sindhu K., et al. Treatment of alopecia areata: An Australian expert consensus statement. *Australas J. Dermatol.* 2019;60:163–170. doi: 10.1111/ajd.12941.
4. A.V. D’Amico, C.G. Roehrborn. Effect of 1mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomized controlled trial *Lancet Oncol*, 8 (2007), pp. 21-25
5. Malik K., Guttman-Yassky E. Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases. *J. Investig. Dermatol. Symp. Proc.* 2018;19:S62–S64. doi: 10.1016/j.jisp.2017.10.005.
6. Plikus MV, et al. Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration. *Nature* 2008;451(7176):340–344
7. Festa E, et al. Adipocyte lineage cells contribute to the skin stem cell niche to drive hair cycling. *Cell* 2011;146(5):761–771.
8. Mecklenburg L, Tobin DJ, Müller-Röver S, Handjiski B, Wendt G, Peters EMJ, Pohl S, Moll I, Paus R. Active hair growth (anagen) is associated with angiogenesis. *Journal of Investigative Dermatology* 2000;114(5):909-916.
9. Ostman J, Arner P, Engfeldt P, Kager L. Regional differences in the control of lipolysis in human adipose tissue. *Metabolism* 1979; 28:1198–1205.
10. Paus R. Principles of hair cycle control. *J Dermatol.* 1998; 25:793–802. [PubMed: 9990771]
11. Enshell-Seijffers D, Lindon C, Morgan BA. The serine protease Corin is a novel modifier of the Agouti pathway. *Development* 2008;135:217–225.
12. Enshell-Seijffers D, Kashiwagi M, Lindon C, Morgan BA. β -catenin activity in the dermal papilla regulates morphogenesis and regeneration of hair. *Developmental Cell* 2010;18:633–642.
13. Driskell RR, Clavel C, Rendl M, et al. Hair follicle dermal papilla cells at a glance. *J Cell Sci.* 2011; 124:1179–1182.
14. Jahoda CA, Horne KA, Oliver RF. Induction of hair growth by implantation of cultured dermal papilla cells. *Nature* 1984;11-17
15. Luanpitpong S, Nimmannit U, Chanvorachote P, Leonard SS, Pongrakhananon V, Wang L, Rojanasakul Y. Hydroxyl radical mediates cisplatin-induced apoptosis in human hair follicle dermal papilla cells and keratinocytes through Bcl-2-dependent mechanism. *Apoptosis* 2011;16(8):769-82.
16. Ramos R, Guerrero-Juarez CF, Plikus MV. Hair follicle signaling networks: a dermal papilla-centric approach. *J Invest Dermatol* 2013;133(10):2306-2308.
17. Eichmüller S, Van Der Veen C, Moll I, et al. Clusters of perifollicular macrophages in normal murine skin: physiological degeneration of selected hair follicles by programmed organ deletion. *J Histochem Cytochem* 1998; 46:361–370.

18. Yanez DA, Lacher RK, Vidyarthi A, Colegio OR. The role of macrophages in skin homeostasis. *Pflugers Arch* 2017;469(3-4):455-463.
19. Parakkal PF. "Role of macrophages in collagen resorption during hair growth cycle." *Journal of ultrastructure research* 1969: 210-217.
20. Stenn KS, Paus R. Controls of hair follicle cycling. *Physiol Rev* 2001; 81:449-494.
21. du Cros DL. Fibroblast growth factor and epidermal growth factor in hair development. *J Invest Dermatol* 1993;101(1):106S-113S.
22. Stevens J, Khetarpal S. Platelet-rich plasma for androgenetic alopecia: A review of the literature and proposed treatment protocol. *Int J Womens Dermatol* 2018;21:5(1):46-51.
23. Chu SY, Chou CH, Huang HD, et al. Mechanical stretch induces hair regeneration through the alternative activation of macrophages. *Nat Commun* 2019;10(1):1524.
24. Fathke C, Wilson L, Hutter J, et al. Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. *Stem Cells* 2004;22:812-822.
25. Loukogeorgakis SP and Paolo DC. "Concise review: amniotic fluid stem cells: the known, the unknown, and potential regenerative medicine applications." *Stem Cells* 2017; 35(7): 1663-1673
26. Brown C, McKee C, Bakshi S, Walker K, Hakman E, Halassy S, et al. Mesenchymal stem cells: cell therapy and regeneration potential. *J Tissue Eng Regen Med.* 2019;13(9):1738-55.
27. De Coppi P, Bartsch G Jr, Siddiqui MM, Xu T, Santos CC, Perin L, et al. Isolation of amniotic stem cell lines with potential for therapy. *Nat Biotechnol* 2007;25(1):100-6.
28. Magatti M, Vertua E, Cargnoni A, Silini A, Parolini O. The immunomodulatory properties of amniotic cells: The two sides of the coin. *Cell Transplant* 2018; 27: 31-44.
29. Moorefield EC. et al. Cloned, CD117 selected human amniotic fluid stem cell are capable of modulating the immune response. *Plos One* 2011;6:1-7.
30. Muttini A, Barboni B, Valbonetti L, Russo V, Maffulli N. Amniotic epithelial stem cells: Salient features and possible therapeutic role. *Sports Med Arthrosc Rev* 2018; 26:70-74.
31. Abbasi-Kangevari M, Ghamari SH, Safaeineja F, Bahrami S, Niknejad H. Potential therapeutic features of human amniotic mesenchymal stem cells in multiple sclerosis: Immunomodulation, inflammation suppression, angiogenesis promotion, oxidative stress inhibition, neurogenesis induction, MMPs regulation, and remyelination stimulation. *Front Immunol* 2019;10: 238.
32. Antonucci I, Provenzano M, Rodrigues M, Pantalone A, Salini V, Ballerini P, et al. Amniotic fluid stem cells: a novel source for modeling of human genetic diseases. *Int J Mol Sci* 2016;17:607.
33. Zentelyte A, Gasiuniene M, Treigyte G, Baronaite S, Savickiene J, Borutinskaite V, et al. Epigenetic regulation of amniotic fluid mesenchymal stem cell differentiation to the mesodermal lineages at normal and fetus-diseased gestation. *J Cell Biochem* 2020;121:1811-1822.
34. Srivastava M.D., Lippes J., Srivastava B. Cytokines of the human reproductive tract. *American Journal of reproductive immunology* 1996: 36: 157-166.
35. Heidari Z., Isobe K., Goto S., Nakashima I., Kiuchi K., Tomoda Y. Characterization of the growth factor activity of amniotic fluid on cells from hematopoietic and lymphoid organs of different life stages. *Microbiology and Immunology* 1996;40: 583-589.
36. Sakuragawa N., Elwan M. A., Fujii T., Kawashima K. Possible dynamic neurotransmitter metabolism surrounding the fetus. *Journal of Child Neurology* 1999;14: 265-266.
37. Bartha JL, Romero-Carmona R, Comino-Delgado R, Arce F, Arraba J. Alpha-fetoprotein and hematopoietic growth factors in amniotic fluid. *Obstet Gynecol* 2000; 96:588-592.
38. Hirai C, et al. (). Trophic effect of multiple growth factors in amniotic fluid or human milk on cultured human fetal small intestinal cells. *J Pediatr Gastroenterol Nutr* 2002;34(5):524-8.
39. Modena AB, Fieni S. Amniotic fluid dynamics. *Acta bio-medica: Atenei Parmensis* 2004;75:11-3.

40. Keller S, Rupp C, Stoeck A et al. CD24 is a marker of exosomes secreted into urine and amniotic fluid. *Kidney Int* 2007; 72: 1095–1102.
41. Yoon BS, Moon J-H, Jun EK, et al. Secretory profiles and wound healing effects of human amniotic fluid-derived mesenchymal stem cells. *Stem Cells Dev* 2010;19:887-902.
42. Beretti F, Zavatti M, Casciaro F, Comitini G, Franchi, F, Barbieri V, La Sala B. Giovanni, Maraldi T. Amniotic fluid stem cell exosomes: Therapeutic perspective. *International Union of Biochemistry and Molecular Biology* 2018;44:158–167
43. Christoph T, Muller-Rover S, Audring H, et al. The human hair follicle immune system: cellular composition and immune privilege. *Br J Dermatol* 2000; 142:862–873.
44. Castellana D, Paus R, Perez-Moreno M. Macrophages contribute to the cyclic activation of adult hair follicle stem cells. *PLoS Biol* 2014; 12:e1002002.
45. Nieves, D. S. et al. Dermatologic and immunologic findings in the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. *Arch. Dermatol.* 140, 466–472 (2004).
46. Pratt, C. H., E, K. L., Messenger, A. G., Christiano, A. M. & Sundberg, J. P. Alopecia areata. *Nat. Rev. Dis. Prim.* 3, 527–535 (2017)
47. Harries, M. J. et al. Lichen planopilaris and frontal fibrosing alopecia as model epithelial stem cell diseases. *Trends Mol. Med.* 24, 435–448 (2018).
48. Sohail A, Richard W, David M. Effect of gamma irradiation on proteases activities in *Musca domestica*. *Biochemical Society Transactions* 1998; 26(4).
49. Jensen TJ, Shui JE, Finck CM. The effect of meconium exposure on the expression and differentiation of amniotic fluid mesenchymal stem cells. *J Neonatal Perinatal Med* 2017;10:313–323.
50. Pişkin A, Altunkaynak BZ, Tümentemur G, Kaplan S, Bülent Yazıcı Ö, Hökelek M. The beneficial effects of *Momordica charantia* (bitter gourd) on wound healing of rabbit skin. *Journal of Dermatological Treatment* 2014; 25:4,350-357.
51. Wang, X., Tredget, EE, Wu, Y. Dynamic signals for hair follicle development and regeneration. *Stem Cells and Development* 2011;21: 7–18.
52. Park J, Jun EK, Son D, et al. Overexpression of Nanog in amniotic fluid-derived mesenchymal stem cells accelerates dermal papilla cell activity and promotes hair follicle regeneration. *Exp Mol Med* 2019;51(7):1-15.
53. Zhang Y, Yan J, Liu Y, Chen Z, Li X, Tang L, Li J, Duan M and Zhang G. Human Amniotic Fluid Stem Cell-Derived Exosomes as a Novel Cell-Free Therapy for Cutaneous Regeneration. *Front Cell Dev Biol* 2021; 9:685873.
54. Choi Yeong Min, Choi Soo Young, Kim Hyonmin, Kim Jeongmin, Sang Ki Mun, An In-sook and Jung Jinhyuk. TGF β family mimetic peptide promotes proliferation of human hair follicle dermal papilla cells and hair growth in C57BL/6 mice. *Biomedical Dermatology* (2018) 2:23
55. Boutard VR, Havouis BFC, Philippe, JP, Moulinoux LB. 1995. Transforming growth factor- β stimulates arginase activity in macrophages: implications for the regulation of macrophage cytotoxicity. *J Immunol* 1995;155: 2077.
56. Yamazaki Masashi, Tsuboi Ryoji, Lee Young Ran, Ishidoh Kazumi, Mitsui Shinichi and Ogawa Hideoki. Hair Cycle-Dependent Expression of Hepatocyte Growth Factor (HGF) Activator, Other Proteinases, and Proteinase Inhibitors Correlates with the Expression of HGF in Rat Hair Follicles. *Journal of Investigative Dermatology Symposium Proceedings* 2000;4(3):312-5
57. Rosenquist TA, Martin GR. Fibroblast growth factor signalling in the hair growth cycle: Expression of the fibroblast growth factor receptor and ligand genes in the murine hair follicle. *Dev Dyn* 1996; 205:379–386
58. Lee YR, Yamazaki M, Mitsui S, Tsuboi R, Ogawa H. Hepatocyte growth factor (hgf) activator expressed in hair follicles is involved in in vitro hgf-dependent hair follicle elongation. *J Dermatol Sci* 2001; 25: 156–163.

59. Yano K, Brown LF, Detmar M: Control of hair growth and follicle size by VEGF-mediated angiogenesis. *J Clin Invest* 2001;107:409–417.
60. Ozeki M, Tabata YJB. Promoted growth of murine hair follicles through controlled release of vascular endothelial growth factor. *Biomaterials* 2002; 23: 2367–2373.
61. Bartels NG, Jahnke I, Patzelt A, et al. Hair shaft abnormalities in alopecia areata evaluated by optical coherence tomography. *Skin Res Technol* 2011;17: 201–205.
62. Kim MJ, Lim C, Lee JY, et al. Visible-to-near IR quantum dot-based hypermulticolor high-content screening of herbal medicines for the efficacy monitoring of hair growth promoting and hair loss inhibition. *J Biomol Screen* 2013; 18: 462–73.
63. Nicu C, O’Sullivan JD, Ramos R, Timperi L, La T, Farjo N, Farjo B, Popl J, Bhogal R, Hardman JA. Dermal adipose tissue secretes hgf to promote human hair growth and pigmentation. *J Investig Dermatol* 2021;141(7):1633-1645.
64. Ozeki M, Tabata Y. In vivo promoted growth of mice hair follicles by the controlled release of growth factors. *Biomaterials* 2003; 24: 2387–94.
65. Yoon SY, Dieterich LC, Karaman S, Proulx ST, Bachmann SB, Sciaroni C, et al. An important role of cutaneous lymphatic vessels in coordinating and promoting anagen hair follicle growth. *PLoS ONE* 2019;14(7).
66. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. *Br J Dermatol* 2004, 150: 186–94. 10.1111/j.1365-2133.2004.05785.x
67. Mirabella T, Cilli M, Carlone S, Cancedda R, Gentili C. Amniotic liquid derived stem cells as reservoir of secreted angiogenic factors capable of stimulating neo-arteriogenesis in an ischemic model. *Biomaterials* 2011;32:3689–3699.
68. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. *J Clin Invest* 1998;101:890–898.
69. Grohmann U, Belladonna ML, Vacca C, et al. Positive Regulatory Role of IL-12 in Macrophages and Modulation by IFN- γ [J]. *The Journal of Immunology* 2001;167(1): 221-227.
70. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, Meerschaut S, Beschin A, Raes G, De Baetselier P. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. *Immunobiology* 2006;211(6-8):487-501.
71. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm [J]. *Nature Immunology* 2010;11(10): 889-896.
72. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. *Front Biosci* 2008;13:453–61.
73. Ishii M, Wen H, Corsa CA, Liu T, Coelho AL, Allen RM, et al. Epigenetic regulation of the alternatively activated macrophage phenotype. *Blood* (2009) 114(15):3244–54. doi:10.1182/blood-2009-04-217620
74. Cao Q, Wang Y, Zheng D, Sun Y, Wang Y, Lee VW, Zheng G, Tan TK, Ince J, Alexander SI, Harris DC. IL-10/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. *J Am Soc Nephrol* 2010;21(6):933-42.
75. Nio Y, Yamauchi T, Iwabu M, Okada-Iwabu M, Funata M, Yamaguchi M, Ueki K, Kadowaki T. Monocyte chemoattractant protein-1 (MCP-1) deficiency enhances alternatively activated M2 macrophages and ameliorates insulin resistance and fatty liver in lipoatrophic diabetic A-ZIP transgenic mice. *Diabetologia* 2012;55:3350–8.
76. Selleri S, Bifsha P, Civini S, Pacelli C, Dieng MM, Lemieux W, Jin P, Bazin R, Patey N, Marincola FM, Moldovan F, Zaouter C, Trudeau LE, et al. Human mesenchymal stromal cell-secreted

- lactate induces M2-macrophage differentiation by metabolic reprogramming. *Oncotarget* 2016;7:30193–210.
77. Zhang Yong-Hong, He Ming, Wang Yan and Liao Ai-Hua. Modulators of the Balance between M1 and M2 Macrophages during Pregnancy *Frontiers in Immunology* 2017; 8:120.
78. Gratchev A. TGF- β signalling in tumor associated macrophages. *Immunobiology* 2017; 222(1):75–81.
79. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. *Immunity* 2010;32(5):593-604
80. Damoiseaux JG, Döpp EA, Calame W, Chao D, MacPherson GG, Dijkstra CD. Rat macrophage lysosomal membrane antigen recognized by monoclonal antibody ED1 *Immunology* 1994;83:140-147
81. Tan JL, Chan ST, Lo CY et al. Amnion cell mediated immune modulation following bleomycin challenge:controlling the regulatory T cell response. *Stem Cell Res Ther* 2015;6: 8.
82. Tan JL, Chan ST,Wallace EM et al. Human amnion epithelial cells mediate lung repair by directly modulating macrophage recruitment and polarization. *Cell Transpl* 2014;23: 319–328.
83. Sica A and Mantovani A. Macrophage plasticity and polarization: In vivo veritas. *J Clin Invest* 2012; 122: 787–795
84. Kronsteiner B, Peterbauer-Scherb A, Grillari-Voglauer R, Redl H, Gabriel C, van Griensven M, et al. Human mesenchymal stem cells and renal tubular epithelial cells differentially influence monocyte-derived dendritic cell differentiation and maturation. *Cell Immunol* 2011; 267(1):30–8.
85. Sedrakyan S, Da Sacco S, Milanese A, et al. Injection of amniotic fluid stem cells delays progression of renal fibrosis. *J Am Soc Nephrol* 2012;23(4):661–673.
86. Magatti M, Caruso M, De Munari S, Vertua E, De D, Manuelpillai U, et al. Human amniotic membrane-derived mesenchymal and epithelial cells exert different effects on monocyte-derived dendritic cell differentiation and function. *Cell Transplant* 2015; 24(9):1733–52.
87. Pianta S, Bonassi Signoroni P, Muradore I, Rodrigues MF, Rossi D, Silini A, et al. Amniotic membrane mesenchymal cells-derived factors skew T cell polarization toward Treg and downregulate 1 and 17 cells subsets. *Stem Cell Rev* 2015;11(3):394–407.
88. Munder MK, Eichmann JM, Moran CG et al. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. *J Immunol* 1999;163: 3771.
89. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. *J Immunol* 2000;164(12):6166-73.
90. Fukui S, Iwamoto N, Takatani A, Igawa T, Shimizu T, Umeda M, Nishino A, Horai Y, Hirai Y, Koga T, Kawashiri SY, Tamai M, Ichinose K, Nakamura H, Origuchi T, Masuyama R, Kosai K, Yanagihara K, Kawakami A. M1 and M2 Monocytes in Rheumatoid Arthritis: A Contribution of Imbalance of M1/M2 Monocytes to Osteoclastogenesis. *Front Immunol* 2018;8:1958.
91. Krzyszczyk P, Schloss R, Palmer A, Berthiaume F. The Role of Macrophages in Acute and Chronic Wound Healing and Interventions to Promote Pro-wound Healing Phenotypes. *Front Physiol* 2018;9:419.
92. Weedon D, and Strutton G. "Apoptosis as the mechanism of the involution of hair follicles in catagen transformation." *Acta Dermato-Venereologica* 1981: 335-339.
93. Paus R, Van Der Veen C, Eichmuller S, et al. Generation and cyclic remodeling of the hair follicle immune system in mice. *J Invest Dermatol* 1998; 111:7–18.
94. Balbi C., Piccoli M., Barile L., Papait A., Armirotti A., et al. First characterization of human amniotic fluid stem cell extracellular vesicles as a powerful paracrine tool endowed with regenerative potential. *Stem Cells Transl Med* 2017;6:1340–1355.
95. Schmidt B and Horsley V. Unraveling hair follicle-adipocyte communication. *Exp Dermatol* 2012; 21(11): 827–830.

96. Driskell RR, Lichtenberger BM, Hoste E, Kretzschmar K, Simons BD, Charalambous M, Ferron SR, Herault Y, Pavlovic G, Ferguson-Smith AC, Watt FM. Distinct fibroblast lineages determine dermal architecture in skin development and repair. *Nature*. 2013 Dec 12;504(7479):277-281. doi: 10.1038/nature12783. PMID: 24336287; PMCID: PMC3868929.
97. Butcher EO (1934) The hair cycles in the albino rat. *Anat Rec* 61(1):5–19.
98. Chase HB, Montagna W, Malone JD. Changes in the skin in relation to the hair growth cycle. *Anat Rec* 1953;116(1):75–81.
99. Hansen LS, Coggle JE, Wells J, Charles MW. The influence of the hair cycle on the thickness of mouse skin. *Anat Rec* 1984;210(4):569–573.
100. Rodeheffer MS, Birsoy K, Friedman JM. Identification of white adipocyte progenitor cells in vivo. *Cell* 2008; 135:240–249.
101. Donati G, Proserpio V, Lichtenberger BM, Natsuga K, Sinclair R, Fujiwara H, Watt FM. Epidermal Wnt/ β -catenin signaling regulates adipocyte differentiation via secretion of adipogenic factors. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111:1501–1509.
102. Driskell RR, Watt FM. Understanding fibroblast heterogeneity in the skin. *Trends Cell Biol* 2015;25(2):92-9.
103. Kruglikov IL, Scherer PE. Dermal adipocytes and hair cycling: is spatial heterogeneity a characteristic feature of the dermal adipose tissue depot? *Experimental Dermatology*. 2016 Apr;25(4):258-262. DOI: 10.1111/exd.12941. PMID: 26781768; PMCID: PMC4805479